Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 851Lung Neoplasms 575Small Cell Lung Carcinoma 164Colorectal Neoplasms 130Breast Neoplasms 104Melanoma 100Neoplasms 91Ovarian Neoplasms 89Neoplasm Metastasis 82Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 68Stomach Neoplasms 59Carcinoma, Renal Cell 54Head and Neck Neoplasms 53Esophageal Neoplasms 48Triple Negative Breast Neoplasms 47Endometrial Neoplasms 47Prostatic Neoplasms 45Uterine Cervical Neoplasms 41Colonic Neoplasms 40Urinary Bladder Neoplasms 39Mesothelioma 38Carcinoma, Hepatocellular 35Mesothelioma, Malignant 34Brain Neoplasms 30Sarcoma 28Carcinoma, Transitional Cell 28Adenocarcinoma of Lung 28Lung Diseases 24Disease 24

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Thoracic × 90 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡